Low total testosterone is associated with increased risk of incident type 2 diabetes mellitus in men: results from the Study of Health in Pomerania (SHIP)

References

• International Diabetes Federation. About Diabetes. 2009. Electronic citation. http://www.idf.org/about_diabetes. Last accessed 5 September 2009.
   Google Scholar
• ShawJE, ChisholmDJ. Epidemiology and prevention of type 2 diabetes and the metabolic syndrome. Med J Aust 2003;179:379–383.
   PubMed Web of Science ®Google Scholar
• CrandallJP, KnowlerWC, KahnSE, MarreroD, FlorezJC, BrayGA, Haffner SM, Hoskin M, Nathan DM. The prevention of type 2 diabetes. Nat Clin Pract Endocrinol Metab 2008;4:382–393.
   PubMedGoogle Scholar
• Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, Rifai N, Buring JE, Gaziano JM, Liu S. Sex Hormone-Binding Globulin and Risk of Type 2 Diabetes in Women and Men. N Engl J Med 2009.
   Google Scholar
• Barrett-ConnorE, KhawKT, YenSS. Endogenous sex hormone levels in older adult men with diabetes mellitus. Am J Epidemiol 1990;132:895–901.
   PubMed Web of Science ®Google Scholar
• LaaksonenDE, NiskanenL, PunnonenK, NyyssonenK, TuomainenTP, ValkonenVP, Salonen R, Salonen JT. Testosterone and sex hormone-binding globulin predict the metabolic syndrome and diabetes in middle-aged men. Diabetes Care 2004;27:1036–1041.
   PubMed Web of Science ®Google Scholar
• DingEL, SongY, MansonJE, HunterDJ, LeeCC, RifaiN, et al. Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 2009;361:1152–1163.
   PubMed Web of Science ®Google Scholar
• StanworthRD, KapoorD, ChannerKS, JonesTH. Androgen receptor CAG repeat polymorphism is associated with serum testosterone levels, obesity and serum leptin in men with type 2 diabetes. Eur J Endocrinol 2008;159:739–746.
   PubMed Web of Science ®Google Scholar
• StanworthRD, JonesTH. Testosterone in obesity, metabolic syndrome and type 2 diabetes. Front Horm Res 2009;3774–3790.
   Google Scholar
• HaffnerSM, ShatenJ, SternMP, SmithGD, KullerL. Low levels of sex hormone-binding globulin and testosterone predict the development of non-insulin-dependent diabetes mellitus in men. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Am J Epidemiol 1996;143:889–897.
   PubMed Web of Science ®Google Scholar
• StellatoRK, FeldmanHA, HamdyO, HortonES, McKinlayJB. Testosterone, sex hormone-binding globulin, and the development of type 2 diabetes in middle-aged men: prospective results from the Massachusetts male aging study. Diabetes Care 2000;23:490–494.
   PubMed Web of Science ®Google Scholar
• Goodman-GruenD, Barrett-ConnorE. Sex differences in the association of endogenous sex hormone levels and glucose tolerance status in older men and women. Diabetes Care 2000;23:912–918.
   PubMed Web of Science ®Google Scholar
• SvartbergJ, JenssenT, SundsfjordJ, JordeR. The associations of endogenous testosterone and sex hormone-binding globulin with glycosylated hemoglobin levels, in community dwelling men. The Tromso Study. Diabetes Metab 2004;30:29–34.
   PubMed Web of Science ®Google Scholar
• OhJY, Barrett-ConnorE, WedickNM, WingardDL. Endogenous sex hormones and the development of type 2 diabetes in older men and women: the Rancho Bernardo study. Diabetes Care 2002;25:55–60.
   PubMed Web of Science ®Google Scholar
• LakshmanKM, BhasinS, AraujoAB. Sex hormone-binding globulin as an independent predictor of incident type 2 diabetes mellitus in men. J Gerontol A Biol Sci Med Sci, 2010;55:503–509.
   Google Scholar
• VikanT, SchirmerH, NjolstadI, SvartbergJ. Low testosterone and sex hormone-binding globulin levels and high estradiol levels are independent predictors of type 2 diabetes in men. Eur J Endocrinol 2010;162:747–754.
   PubMed Web of Science ®Google Scholar
• ChenRY, WittertGA, AndrewsGR. Relative androgen deficiency in relation to obesity and metabolic status in older men. Diabetes Obes Metab 2006;8:429–435.
   PubMed Web of Science ®Google Scholar
• LaaksonenDE, NiskanenL, PunnonenK, NyyssonenK, TuomainenTP, ValkonenVP, SalonenJT. The metabolic syndrome and smoking in relation to hypogonadism in middle-aged men: a prospective cohort study. J Clin Endocrinol Metab 2005;90:712–719.
   PubMed Web of Science ®Google Scholar
• HaringR, VolzkeH, FelixSB, SchipfS, DorrM, RosskopfD, Nauck M, Schofl C, Wallaschofski H. Prediction of metabolic syndrome by low serum testosterone levels in men: results from the study of health in Pomerania. Diabetes 2009;58:2027–2031.
   PubMed Web of Science ®Google Scholar
• MatsumotoAM, BremnerWJ. Serum testosterone assays – accuracy matters. J Clin Endocrinol Metab 2004;89:520–524.
   PubMed Web of Science ®Google Scholar
• MinerMM, SadovskyR. Evolving issues in male hypogonadism: evaluation, management, and related comorbidities. Cleve Clin J Med 2007;74 (Suppl 3)S38–S46.
   PubMedGoogle Scholar
• BhasinS, CunninghamGR, HayesFJ, MatsumotoAM, SnyderPJ, SwerdloffRS, MontoriVM. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:2536–2559.
   PubMed Web of Science ®Google Scholar
• World Health Organisation. Definition, diagnosis, and classification of diabetes mellitus and its complications: report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. GenevaWHO Department of Noncummunicable Disease Surveillance/NCD/NCS1999; 1–59.
   Google Scholar
• JankowskaEA, BielB, MajdaJ, SzklarskaA, LopuszanskaM, MedrasM, Anker SD, Banasiak W, Poole-Wilson PA, Ponikowski P. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation 2006;114:1829–1837.
   PubMed Web of Science ®Google Scholar
• SchatzlG, MadersbacherS, TemmlC, Krenn-SchinkelK, NaderA, SregiG, Lapin A, Hermann M, Berger P, Marberger M. Serum androgen levels in men: impact of health status and age. Urology 2003;61:629–633.
   PubMed Web of Science ®Google Scholar
• CarruthersM, TrinickTR, WheelerMJ. The validity of androgen assays. Aging Male 2007;10:165–172.
   PubMed Web of Science ®Google Scholar
• GreenlandS, PearlJ, RobinsJM. Causal diagrams for epidemiologic research. Epidemiology 1999;10:37–48.
   PubMed Web of Science ®Google Scholar
• RoystonP, AltmanDG, SauerbreiW. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006;25:127–141.
   PubMed Web of Science ®Google Scholar
• VeölzkeH, AlteD, SchmidtCO, RadkeD, LorbeerR, FriedrichN, et al. Cohort profile: The Study of Health in Pomerania (SHIP). Int J Epidemiol 2010;39:1–14.
   Google Scholar
• MelamedS, ShiromA, TokerS, ShapiraI. Burnout and risk of type 2 diabetes: a prospective study of apparently healthy employed persons. Psychosom Med 2006;68:863–869.
   PubMed Web of Science ®Google Scholar
• SvartbergJ, von MuhlenD, SundsfjordJ, JordeR. Waist circumference and testosterone levels in community dwelling men. The Tromso study. Eur J Epidemiol 2004;19:657–663.
   PubMed Web of Science ®Google Scholar
• FarrellJB, DeshmukhA, BaghaieAA. Low testosterone and the association with type 2 diabetes. Diabetes Educ 2008;34:799–806.
   Google Scholar
• WangC, CatlinDH, DemersLM, StarcevicB, SwerdloffRS. Measurement of total serum testosterone in adult men: comparison of current laboratory methods versus liquid chromatography-tandem mass spectrometry. J Clin Endocrinol Metab 2004;89:534–543.
   PubMed Web of Science ®Google Scholar
• AraujoAB, O'DonnellAB, BrambillaDJ, SimpsonWB, LongcopeC, MatsumotoAM, McKinlayJB. Prevalence and incidence of androgen deficiency in middle-aged and older men: estimates from the Massachusetts Male Aging Study. J Clin Endocrinol Metab 2004;89:5920–5926.
   PubMed Web of Science ®Google Scholar
• PetakSM, NankinHR, SparkRF, SwerdloffRS, Rodriguez-RigauLJ. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for the evaluation and treatment of hypogonadism in adult male patients – 2002 update. Endocr Pract 2002;8:440–456.
   PubMedGoogle Scholar
• KapoorD, AldredH, ClarkS, ChannerKS, JonesTH. Clinical and biochemical assessment of hypogonadism in men with type 2 diabetes: correlations with bioavailable testosterone and visceral adiposity. Diabetes Care 2007;30:911–917.
   PubMed Web of Science ®Google Scholar